pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Immuno-oncology
drug
save

Immuno-oncology

Preclinicalupdated 6mo ago
by American Gene Technologies International Inc
Preclinical
community read0 votes

indications

indications
Breast CancerProstate Cancer

all catalysts(0)

nothing on the calendar yet

Trials studying Immuno-oncology

  • —Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%active not recruitingn=300
  • phase2Safety and Efficacy Study of IMSA101 in Refractory Malignanciescompletedn=40
  • —Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCCcompletedn=355

News(10)

  • FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
    The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…
    fiercebiotech · 3d ago
  • BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
    BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…
    fiercebiotech · 6d ago
  • Beyond the needle: The future of intratumoral therapy
    In this episode of Denatured, you’ll hear from from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratum…
    biospace · 12d ago
  • Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
    With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…
    biospace · 15d ago
  • Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
    Astellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.
    biospace · 19d ago
  • Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences
    Astellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences. The deal features $285 million that covers the upfront fee and a pay…
    endpoints · 20d ago
  • Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
    Astellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.
    fiercebiotech · 20d ago
  • ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
    Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first…
    biospace · 21d ago
  • ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
    After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last w…
    biospace · 21d ago
  • Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
    Another day, another Roche deal. The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell engager (TCE) that could go head-to-head with…
    endpoints · 24d ago
view all news mentions →
indication
Breast Cancer
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?